NO320611B1 - Anvendelse av komponent B for fremstilling av et medikament som kan benyttes som cicatrisant og ved behandling av sar. - Google Patents
Anvendelse av komponent B for fremstilling av et medikament som kan benyttes som cicatrisant og ved behandling av sar. Download PDFInfo
- Publication number
- NO320611B1 NO320611B1 NO19984965A NO984965A NO320611B1 NO 320611 B1 NO320611 B1 NO 320611B1 NO 19984965 A NO19984965 A NO 19984965A NO 984965 A NO984965 A NO 984965A NO 320611 B1 NO320611 B1 NO 320611B1
- Authority
- NO
- Norway
- Prior art keywords
- component
- day
- days
- wound
- treatment
- Prior art date
Links
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 7
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 6
- 239000003814 drug Substances 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 5
- 206010052428 Wound Diseases 0.000 claims abstract description 35
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 35
- 230000003902 lesion Effects 0.000 claims abstract description 5
- 230000000472 traumatic effect Effects 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 238000002474 experimental method Methods 0.000 description 37
- 230000000694 effects Effects 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 230000029663 wound healing Effects 0.000 description 15
- 230000000699 topical effect Effects 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 229940098773 bovine serum albumin Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 7
- 229960002537 betamethasone Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101100005306 Mus musculus Ctso gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dental Preparations (AREA)
- Glass Compositions (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1996/001702 WO1997039765A1 (en) | 1996-04-24 | 1996-04-24 | Component b as cicatrizant |
| CA002251356A CA2251356A1 (en) | 1996-04-24 | 1996-04-24 | Component b as cicatrizant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO984965D0 NO984965D0 (no) | 1998-10-23 |
| NO984965L NO984965L (no) | 1998-12-01 |
| NO320611B1 true NO320611B1 (no) | 2005-12-27 |
Family
ID=25680594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19984965A NO320611B1 (no) | 1996-04-24 | 1998-10-23 | Anvendelse av komponent B for fremstilling av et medikament som kan benyttes som cicatrisant og ved behandling av sar. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5998364A (de) |
| EP (1) | EP0895478B1 (de) |
| JP (1) | JP3882943B2 (de) |
| AT (1) | ATE234110T1 (de) |
| AU (1) | AU727618B2 (de) |
| CA (1) | CA2251356A1 (de) |
| DE (1) | DE69626691T2 (de) |
| DK (1) | DK0895478T3 (de) |
| EA (1) | EA001077B1 (de) |
| ES (1) | ES2188754T3 (de) |
| IL (1) | IL120696A (de) |
| NO (1) | NO320611B1 (de) |
| WO (1) | WO1997039765A1 (de) |
| ZA (1) | ZA973442B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69903037T2 (de) * | 1998-07-09 | 2003-06-05 | Applied Research Systems Ars Holding N.V., Curacao | Komponente b als angiogenes mittel zusammen mit humanen wachstumsfaktoren |
| ATE494903T1 (de) | 2003-04-16 | 2011-01-15 | Merck Serono Sa | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE53166B1 (en) * | 1980-08-05 | 1988-08-03 | Searle & Co | Synthetic urogastrone gene,corresponding plasmid recombinants,transformed cells,production thereof and urogastrone expression |
| IT1257184B (it) * | 1992-12-22 | 1996-01-10 | Applied Research Systems | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
-
1996
- 1996-04-24 EA EA199800953A patent/EA001077B1/ru not_active IP Right Cessation
- 1996-04-24 DE DE69626691T patent/DE69626691T2/de not_active Expired - Fee Related
- 1996-04-24 ES ES96914107T patent/ES2188754T3/es not_active Expired - Lifetime
- 1996-04-24 JP JP50603797A patent/JP3882943B2/ja not_active Expired - Fee Related
- 1996-04-24 US US09/171,659 patent/US5998364A/en not_active Expired - Fee Related
- 1996-04-24 EP EP96914107A patent/EP0895478B1/de not_active Expired - Lifetime
- 1996-04-24 WO PCT/EP1996/001702 patent/WO1997039765A1/en active IP Right Grant
- 1996-04-24 AT AT96914107T patent/ATE234110T1/de not_active IP Right Cessation
- 1996-04-24 AU AU57605/96A patent/AU727618B2/en not_active Ceased
- 1996-04-24 DK DK96914107T patent/DK0895478T3/da active
- 1996-04-24 CA CA002251356A patent/CA2251356A1/en not_active Abandoned
-
1997
- 1997-04-17 IL IL12069697A patent/IL120696A/en not_active IP Right Cessation
- 1997-04-22 ZA ZA9703442A patent/ZA973442B/xx unknown
-
1998
- 1998-10-23 NO NO19984965A patent/NO320611B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA001077B1 (ru) | 2000-10-30 |
| EP0895478A1 (de) | 1999-02-10 |
| AU5760596A (en) | 1997-11-12 |
| AU727618B2 (en) | 2000-12-14 |
| DE69626691D1 (de) | 2003-04-17 |
| EA199800953A1 (ru) | 1999-04-29 |
| NO984965L (no) | 1998-12-01 |
| CA2251356A1 (en) | 1997-10-30 |
| EP0895478B1 (de) | 2003-03-12 |
| JP2000510436A (ja) | 2000-08-15 |
| IL120696A0 (en) | 1997-08-14 |
| DK0895478T3 (da) | 2003-06-23 |
| ZA973442B (en) | 1998-02-23 |
| ATE234110T1 (de) | 2003-03-15 |
| WO1997039765A1 (en) | 1997-10-30 |
| US5998364A (en) | 1999-12-07 |
| DE69626691T2 (de) | 2003-08-14 |
| IL120696A (en) | 2001-10-31 |
| ES2188754T3 (es) | 2003-07-01 |
| NO984965D0 (no) | 1998-10-23 |
| JP3882943B2 (ja) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0699322B2 (ja) | 傷の治癒 | |
| KR20110095867A (ko) | 유착 치료 또는 예방용 폴리펩티드 | |
| JP2017025076A (ja) | 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用 | |
| JP2011507858A (ja) | 整形外科状態の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた、抗コネキシンペプチドの使用 | |
| WO2008037262A1 (en) | Wound healing composition comprising phosphate, iron and copper | |
| JPH05500356A (ja) | 創傷の治癒 | |
| JP5208135B2 (ja) | 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物 | |
| DE69627191T2 (de) | Bradikininanaloge als selektive thrombininhibitoren | |
| JPH04211019A (ja) | 創傷治癒促進のためのトロンボスポンデインの使用 | |
| US7645733B2 (en) | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions | |
| KR101736280B1 (ko) | 관절염 예방 또는 치료용 약학적 조성물 | |
| NO320611B1 (no) | Anvendelse av komponent B for fremstilling av et medikament som kan benyttes som cicatrisant og ved behandling av sar. | |
| DE69330960T2 (de) | Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil | |
| AU2022204563B2 (en) | Application and method of superoxide dismutase in preparing medicine for treating psoriasis | |
| Anderson et al. | Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation | |
| Kovalyova et al. | Enzyme therapy is a highly effective and environmentally safe method of treating lacerated wounds in dogs | |
| JPS61293925A (ja) | 骨及び腱修復促進剤 | |
| WO1995007710A1 (fr) | Remede pour le soin de plaies | |
| Reuben et al. | Compartment syndrome after thrombolysis for acute myocardial infarction | |
| KR100413844B1 (ko) | 반흔형성제인성분b | |
| CN106518972B (zh) | 含有磷酸化酪氨酸的多肽、其应用及药物组合物 | |
| AU2004206971B8 (en) | Method of treatment of conditions by administration of streptolysin O | |
| DE102014112212A1 (de) | Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen | |
| UA56166C2 (uk) | Компонент в як агент, що рубцює | |
| CN114601788A (zh) | 一种鹿茸多肽单体凝胶制剂及其在软骨修复及抗衰老中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
| CREP | Change of representative |
Representative=s name: BRYN AARFLOT AS, POSTBOKS 443 SENTRUM, 0104 OSLO, |